Study of D-2570 for active lupus
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new oral medication called D-2570 for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms while you continue your current stable treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have been diagnosed with lupus (SLE) for at least 24 weeks (about 6 months).
- Your lupus symptoms must be moderately to severely active, as measured by a standard score of 8 or more on the SLEDAI-2K scale.
- Your lupus medications must be at a steady dose for at least 4 weeks before starting the trial.
- You should not have a recent serious infection or any uncontrolled medical condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
This trial tests how a drug called D-2570 is processed in people with different levels of liver function. It compares people with liver impairment to those with healthy livers to see how the drug moves through the body.
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Hear when a new Active Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.